Syros Pharmaceuticals Inc (LTS:0LC7)
$ 2.5409 0.0718 (2.91%) Market Cap: 67.89 Mil Enterprise Value: 69.84 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 28/100

Q4 2023 Syros Pharmaceuticals Inc Earnings Call Transcript

Mar 27, 2024 / 12:30PM GMT
Release Date Price: $5.67 (-9.80%)
Operator

Good morning, and welcome to Seres Pharmaceuticals' Fourth Quarter and Full Year 2023 financial results conference call.

At this time, all participants are in a listen only mode. This call is being webcast live on the Investors and Media section of CAE's website at www.cirrus.com. Please be advised that today's call is being recorded. And at this time, I would like to turn the call over to Karen minority, Director of Investor Relations and Corporate Communications.

Yes, thank you.

Karen Hunady Syros Pharmaceuticals Inc;Director of Investor Relations;Corporate Communications

&

This morning we issued a press release announcing our fourth quarter and full year 2023 financial results. The full release is available on the Investor & Media section of the Cirrus this website at www.cirrus.com. We will begin the call with prepared remarks by timely team, our Chief Executive Officer, Dr. David Roth

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot